Pine Valley Investments Ltd Liability Co decreased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 4.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 72,077 shares of the company’s stock after selling 3,483 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in AbbVie were worth $18,137,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after acquiring an additional 3,032,438 shares in the last quarter. State Street Corp grew its stake in shares of AbbVie by 1.4% in the 4th quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after acquiring an additional 1,119,274 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of AbbVie by 1.4% in the fourth quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. Finally, Norges Bank bought a new position in shares of AbbVie during the fourth quarter valued at about $5,865,055,000. Institutional investors own 70.23% of the company’s stock.
AbbVie Trading Up 2.6%
NYSE:ABBV opened at $265.63 on Thursday. The stock has a market capitalization of $469.31 billion, a PE ratio of 75.04, a price-to-earnings-growth ratio of 0.86 and a beta of 0.30. The firm’s 50 day moving average is $246.98 and its 200 day moving average is $226.95. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47.
AbbVie Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s dividend payout ratio is presently 195.48%.
Analyst Ratings Changes
A number of brokerages have issued reports on ABBV. JPMorgan Chase & Co. upped their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wells Fargo & Company lifted their target price on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research report on Monday. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. UBS Group upped their target price on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Finally, DZ Bank raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $275.73.
View Our Latest Stock Analysis on ABBV
Insider Buying and Selling at AbbVie
In related news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.
More AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie completed a multibillion-dollar senior notes offering to help finance its acquisition of Apogee Therapeutics. The transaction provides funding for the deal and supports AbbVie’s strategy of expanding its immunology and specialty medicines portfolio as it seeks new growth opportunities. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition AbbVie Raises $9 Billion Debt to Fund Acquisition
- Neutral Sentiment: The Apogee financing also introduces additional leverage. While debt allows AbbVie to pursue the acquisition without issuing equity, investors will assess the impact of higher interest costs and whether Apogee’s pipeline generates sufficient returns to justify the transaction. AbbVie Completes $10 Billion Senior Notes Offering to Support Apogee Therapeutics Acquisition
- Neutral Sentiment: AbbVie announced its 2026 Immunology Scholarship recipients, continuing a 10-year community-support program. The announcement reinforces corporate reputation but is unlikely to materially affect earnings or the stock’s near-term valuation. AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients
- Negative Sentiment: Executive Vice President Nicholas Donoghoe sold 32,710 ABBV shares for approximately $8.18 million, reducing his holdings by about 30.5%. Insider sales can reflect personal financial planning, but the sizable transaction may create a modest negative sentiment signal for investors. AbbVie Insider Transaction
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More
- Five stocks we like better than AbbVie
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
